{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.91","upperLimit":"4.90","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"682"}],"units":"Participants"}],"description":"Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide (POM) by mouth (PO) on Days 1 to 21 of each 28-day treatment cycle and low dose dexamethasone (LD-Dex) PO at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle until the documentation of confirmed progressive disease (PD), intolerable toxicity, death, withdrawal of participation in the study/consent, lost to follow-up, or as long as they benefited from therapy according to the opinion of the responsible study investigator.","id":"OG000","title":"Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)"}],"paramType":"MEDIAN","populationDescription":"The intent to treat (ITT) population was defined as all enrolled participants (participants who received an interactive voice response system (IVRS) enrollment date) regardless of whether they received any investigational product (IP) or not.","reportingStatus":"POSTED","timeFrame":"From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months","title":"Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines","type":"SECONDARY","unitOfMeasure":"Months"}